

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371</b>		Attorney Docket Number  9150-0008.10
		U.S. Application No. (if known, see 37 CFR §1.5) <b>09/555704</b>
International Application No.  PCT/JP99/02931	International Filing Date  June 2, 1999	Priority Date Claimed  October 5, 1998
Title of Invention  <b>EHHANCED IMMUNOGEN FOR INACTIVATED VACCINE FOR INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES AND PROCESS FOR PRODUCING THE SAME</b>		
Applicant(s) for DO/EO/US  <b>Toyokazu Ishikawa, Hironori Yoshii, Toshiyuki Onishi, Tadashi Imagawa, Masahide Ishibashi</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information		
1.	<input checked="" type="checkbox"/>	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. §371.
2.	<input type="checkbox"/>	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. §371.
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
	<input type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. §371(c)(2))
	a.	<input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).
	b.	<input checked="" type="checkbox"/> has been transmitted by the International Bureau.
	c.	<input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. §371(c)(2)).
	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
	a.	<input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).
	b.	<input type="checkbox"/> have been transmitted by the International Bureau.
	c.	<input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.
	d.	<input type="checkbox"/> have not been made and will not be made.
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9.	<input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)) (unsigned).
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).
Items 11. to 16. below concern document(s) or information included:		
11.	<input type="checkbox"/>	An Information Disclosure Statement under 37 CFR §1.97 and §1.98.
12.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR §3.28 and §3.31 is included.
13.	<input checked="" type="checkbox"/>	A <b>FIRST</b> preliminary amendment.
	<input type="checkbox"/>	A <b>SECOND</b> or <b>SUBSTITUTE</b> preliminary amendment.
14.	<input type="checkbox"/>	A substitute specification.
15.	<input type="checkbox"/>	A change of Power of Attorney and/or Address letter.
16.	<input checked="" type="checkbox"/>	Other items or information: 1 sheet of drawings, Certificate of Express Mail

U.S. Application No. (if known, see 37 CFR §1.5) <div style="font-size: 24pt; font-weight: bold; margin-top: 10px;">09/555704</div>	International Application No. <div style="text-align: center; font-weight: bold; margin-top: 10px;">PCT/US99/02931</div>	Attorney's Pocket No. <div style="text-align: center; font-weight: bold; margin-top: 10px;">9150-0008.10</div>																																																																	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE</b> (37 CFR §1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO ..... \$ 640.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) ..... ..... \$ 670.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2)) ..... \$ 760.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO ..... \$970.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$ 96.00 <div style="text-align: right; margin-top: 10px;">ENTER APPROPRIATE BASIC FEE AMOUNT = \$840.00</div>		<b>CALCULATIONS</b> <span style="float: right;">PTO USE ONLY</span> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;"></th> </tr> <tr> <td>Total Claims</td> <td>15 - 20 =</td> <td>0</td> <td>0 x \$ 18.00</td> <td>\$ 00.00</td> </tr> <tr> <td>Independent Claims</td> <td>4 - 3 =</td> <td>1</td> <td>1 x \$ 78.00</td> <td>\$ 78.00</td> </tr> <tr> <td>Multiple Dependent Claim(s) (if applicable)</td> <td></td> <td></td> <td>+ \$260.00</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td><b>\$918.00</b></td> </tr> <tr> <td colspan="4">Reduction of fee for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR §1.9, §1.29, §1.28)</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>SUBTOTAL =</b></td> <td><b>\$</b></td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than 20 months from the earliest claimed priority date (37 CFR §1.942(f)).</td> <td>\$</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR §3.28, §3.31). \$40.00 per property.</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b></td> <td><b>\$918.00</b></td> </tr> <tr> <td colspan="4"></td> <td>Amount to be:</td> </tr> <tr> <td colspan="4"></td> <td>    refunded \$</td> </tr> <tr> <td colspan="4"></td> <td>    charged \$</td> </tr> </table></div>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total Claims	15 - 20 =	0	0 x \$ 18.00	\$ 00.00	Independent Claims	4 - 3 =	1	1 x \$ 78.00	\$ 78.00	Multiple Dependent Claim(s) (if applicable)			+ \$260.00	\$	<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$918.00</b>	Reduction of fee for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR §1.9, §1.29, §1.28)				\$	<b>SUBTOTAL =</b>				<b>\$</b>	Processing fee of \$130.00 for furnishing the English translation later than 20 months from the earliest claimed priority date (37 CFR §1.942(f)).				\$	Fee for recording the enclosed assignment (37 CFR §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR §3.28, §3.31). \$40.00 per property.				\$	<b>TOTAL FEES ENCLOSED =</b>				<b>\$918.00</b>					Amount to be:					refunded \$					charged \$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																
Total Claims	15 - 20 =	0	0 x \$ 18.00	\$ 00.00																																																															
Independent Claims	4 - 3 =	1	1 x \$ 78.00	\$ 78.00																																																															
Multiple Dependent Claim(s) (if applicable)			+ \$260.00	\$																																																															
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$918.00</b>																																																															
Reduction of fee for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR §1.9, §1.29, §1.28)				\$																																																															
<b>SUBTOTAL =</b>				<b>\$</b>																																																															
Processing fee of \$130.00 for furnishing the English translation later than 20 months from the earliest claimed priority date (37 CFR §1.942(f)).				\$																																																															
Fee for recording the enclosed assignment (37 CFR §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR §3.28, §3.31). \$40.00 per property.				\$																																																															
<b>TOTAL FEES ENCLOSED =</b>				<b>\$918.00</b>																																																															
				Amount to be:																																																															
				refunded \$																																																															
				charged \$																																																															
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$218.00</u> to cover the filing fees is enclosed. b. <input type="checkbox"/> Please charge Deposit Account No. <u>04-0531</u> in the amount of \$ to cover the above fees. This sheet is provided in triplicate. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>04-0531</u> . This sheet is provided in triplicate. <div style="margin-top: 10px;">NOTE: Where an appropriate time limit under 37 CFR §1.494 or §1.495 has not been met, a petition to revive (37 CFR §1.137(a) or (b)) must be filed and granted to restore the application to pending status.</div>																																																																			
SEND ALL CORRESPONDENCE TO: <div style="margin-top: 20px;">             Iota P1 Law Group              P.O. Box 60850              Palo Alto, CA 94306              Customer No. 22918  <div style="font-weight: bold; font-size: 1.2em;">(415) 324-0880</div> </div>			<div style="text-align: center; margin-top: 20px;">               Signature           </div> <div style="margin-top: 10px;">             Name: <u>Judy M. Mohr</u>              Registration No.: <u>38,563</u> </div>																																																																

09/555704

1/PART

422 Rec'd PCT/PTO 02 JUN 2000

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 6-2-00

By: Larry Thon

DOCKET No.: 9150-0008.10

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## IN RE APPLICATION OF:

Ishikawa, T. et al.

EXAMINER: unknown

SERIAL No.: unknown

ART UNIT: unknown

FILED: concurrently herewith

FOR: ENHANCED IMMUNOGEN FOR  
INACTIVATED VACCINE FOR INFECTION  
WITH JAPANESE ENCEPHALITIS  
VIRUSES AND PROCESS FOR PRODUCING  
THE SAME

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Before examination of the above-noted application, please  
amend the application as follows.

In the specification:

On page 1, before line 1, insert --This application claims  
priority to application no. PCT/JP99/02931 filed June 2, 1999, now  
publication no. WO 00/20565 published April 13, 2000; which claims  
priority to JP 10-319762 filed October 5, 1998, which are both  
incorporated herein by reference.--

In the Claims: Cancel claim 8, without prejudice, amend claims 4,  
5, 6, 7, 9 and 10 and add new claims 11-16 as follows:

In claim 4, line 1 thereof, delete "or 3".

09555704 060200

5. (Amended) The method of [any of claims] claim 2 [to 4], wherein the inactivating is conducted at a temperature in a range of about 40°C to about 100°C.

6. (Amended) The method of [any of claims] claim 2 [to 5], wherein the purifying is conducted by physical means.

7. (Amended) The method of [any of claims] claim 2 [to 6], wherein the virus belonging to a group of Japanese encephalitis viruses is a Beijing strain or a ThCMAR67/93 strain of Japanese encephalitis virus.

In claim 9, line 2 thereof, delete "or 8".

In claim 10, line 4 thereof, change "8" to --1--.

--11. The inactivated virus particle of claim 1, wherein said culture of cells is inactivated and purified.

12. The inactivated virus particle of claim 1, wherein said culture of cells is inactivated and then purified.

13. The inactivated virus particle of claim 11, wherein said cells are inactivated at a temperature in a range of about 40°C to about 100°C.

14. The inactivated virus particle of claim 11, wherein the cells are purified by physical means.

15. The inactivated virus particle of claim 1, wherein said culture of cells is a culture of Vero cells.

16. The inactivated virus particle of claim 1, wherein the virus belonging to a group of Japanese encephalitis viruses is a

Beijing strain or a ThCMAR67/93 strain of Japanese encephalitis virus.--

**REMARKS**

The claims have been amended to remove multiple dependencies. Entry of the amendments prior to examination is respectfully requested.

The Examiner is invited to contact Applicants' representative at 650-324-0880 if prosecution of this application would be assisted thereby.

Respectfully submitted,



Judy M. Mohr  
Registration No. 38,563

Date: June 2, 2000

**Correspondence Address**  
Customer No. 22918



Attorney Docket No.: 9150-0008.10

Applicant: Toyokazu Ishikawa, et al.

Serial No.: 09/555,704

Filing Date June 2, 2000

For: **ENHANCED IMMUNOGEN FOR INACTIVATED VACCINE FOR INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES AND PROCESS FOR PRODUCING THE SAME**

**Small Entity Statement Under**  
**37 CFR §1.9(f) and §1.27(c) - Nonprofit Organization**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: **THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY**

Address of Organization: c/o Osaka University 3-1, Yamadaoka, Suita-shi,  
Osaka 565-0871 Japan

- ☒ University or other institution of higher education.
- ☐ Tax exempt under Internal Revenue Service Code (26 USC §501(a) and §501(c)(3)).
- ☐ Nonprofit scientific or educational under statute of state of the United States of America.
- ☐ Name of State: ☐ Citation of Statute:
- ☐ Would qualify as tax-exempt under Internal Revenue Service Code (26 USC §501(a) and §501(c)(3)) if located in The United States of America.
- ☐ Would qualify as nonprofit scientific or educational non-profit under statute of state of The United States of America if located in The United States of America.
- ☐ Name of State: ☐ Citation of Statute:

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9 (e), for purposes of paying reduced fees under 35 U.S.C. §41 to the U.S. Patent and Trademark Office in connection with the invention described in the above-referenced application. If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person; other than the inventor, who could not qualify as a small business concern under 37 CFR §1.9 (d) or by any concern which would not qualify as an independent inventor under 37 CFR §1.9 (c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR §1.9 (d) or a nonprofit organization under 37 CFR §1.9 (e).

NOTE: Separate Verified Statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR §1.27).

09555704.06000

THE RESEARCH FOUNDATION FOR MICROBIAL

NAME: DISEASES OF OSAKA UNIVERSITY

Address: c/o Osaka University 3-1, Yamadaoka, Suita-shi,  
Osaka 565-0871 Japan

☐ individual ☐ small business concern ☒ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR §1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.

Name of person signing: Yasushi HIGASHI

Title of person signing: Director General

Address of person signing: c/o Osaka University 3-1, Yamadaoka, Suita-shi,  
Osaka 565-0871 Japan

Signature: Yasushi Higashi Date: July 24, 2000

09/555704  
Rec'd PCT/PTO 07 NOV 2000  
OBK001

0955704 050200  
ENHANCED IMMUNOGEN FOR INACTIVATED VACCINE  
FOR INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES  
AND PROCESS FOR PRODUCING THE SAME



## BACKGROUND OF THE INVENTION

## FIELD OF THE INVENTION:

5 The present invention relates to an inactivated vaccine against infectious disease caused by a group of Japanese encephalitis viruses of *Flavivirus*, and a diagnostic agent thereof. In particular, the present invention relates to an inactivated vaccine against Japanese encephalitis, a reinforced immunogen or antigen which is outstanding and useful as an active ingredient of the vaccine, 10 and a method for producing the immunogen or antigen.

## DESCRIPTION OF THE RELATED ART:

Hereinafter, as a representative example of infectious disease caused by a group of Japanese encephalitis viruses, Japanese encephalitis will be 15 illustrated, and a vaccine against it will be described. The first Japanese encephalitis vaccine was put into practical use in 1954. This vaccine contains, as its active ingredient, an antigen prepared from virus cultured in mouse 20 brain. The purity of such a vaccine is low, and such a vaccine contains a lot of contamination, so that it might induce an allergic neurological disorder in the central nervous system. Thereafter, an improved high-purity vaccine obtained by the combination of alcohol sedimentation, 25 treatment with protamine sulfate, ultra-centrifugation, and the like was put into practical use in 1965. Thus, the quality of the vaccine was remarkably improved. Such a vaccine and a production technique therefor have been utilized up to now ("Vaccine Handbook", pp. 103-113, 30 Researcher's Associates, the National Institute of Health (Japan), Maruzen (Tokyo) 1996). On the other hand, there were attempts to develop an inactivated vaccine obtained without using mouse brain. More specifically, the

09556704.050200

Committee on Japanese Encephalitis Vaccine was established in 1965, and they developed a vaccine using primary cell tissue culture. However, in terms of production cost, it was practically impossible to obtain the large amount of primary cell cultures required for large-scale production of inactivated vaccine antigens. Such a vaccine was not put into practical use, because at that time, only primary culture cells were approved for production of vaccines, and the use of a passage cell line was considered to be dangerous and was not permitted. Regarding a Japanese encephalitis live vaccine obtained using tissue culture, a live vaccine using, as its active ingredient, an attenuated virus grown in primary culture of hamster renal cells in China was put into practical use in China at around 1994. However, effectiveness and safety of the live vaccine have not been confirmed, and its use in various countries other than China, is not known. Furthermore, various Japanese encephalitis vaccines obtained by recombinant gene techniques (e.g., the second generation vaccine using an envelope (E) protein antigen, recombinant virus, or the like) have been reported since about 1986. However, all of these vaccines are in the experimental stage or a pre-clinical trial stage, and they have not been put into practical use ("Vaccine", 2nd ed., pp. 671-713, S.A. Plotkin and E.A. Mortimer, W.B. Saunders Co. 1994; The Jordan Report, pp. 26-27, 1998).

Furthermore, regarding a technique of using a cell line for large-scale production of antigens or immunogens for an inactivated vaccine, for example, it is known to use a Vero cell for large-scale production of virus antigens used in vaccines against poliomyelitis (U.S. Patent No. 4,525,349), rabies (U.S. Patent No. 4,664,912), Hepatitis A (U.S. Patent No. 4,783,407), and tick-borne

encephalitis (U.S. Patent No. 5,719,051), and the like. Among these, it is well-known that the former two have already been put into practical use. However, regarding the latter two, the safety and effectiveness as a vaccine of each antigen produced on a large scale have not been confirmed, and have not been put into practical use.

An active ingredient of a conventional Japanese encephalitis vaccine is inactivated particles of Japanese encephalitis virus grown in mouse brain. A large number of mice, measures against biohazard of infected animals, and the like are required for large-scale production of antigens for such a vaccine, which results in a high production cost. Furthermore, contamination into the product of adverse components derived from mouse brain (e.g., a basic protein which causes demyelination), and/or contamination of virus from a mouse, and the like, are always likely to be a factor. Therefore, purification steps and quality control become diverse and complicated. In addition, recently, it is difficult to obtain a large number of mice for production of vaccines, which becomes an obstacle to planned vaccine production. Furthermore, a conventional technique which sacrifices mice is becoming undesirable in view of animal protection and religion.

#### SUMMARY OF THE INVENTION

According to the present invention, virus particles are produced on a large scale by using a cell line in place of a mouse in order to solve the above problems. Because of this, the production cost can be remarkably reduced, and measures against biohazards, the operation procedure for production, purification steps, quality control, the

production plan, and the like are remarkably efficient with respect to labor cost. In particular, the present invention is based on an unpredictable discovery of novel virus particles. More specifically, according to the present invention, novel virus particles, as a reinforced immunogen in which immunopotency represented as a neutralizing antibody titer is reinforced from about twice to about 10 times compared with an immunogen contained in a conventional inactivated vaccine, and a method for producing the same are provided. That is, novel Japanese encephalitis virus particles having outstanding immunogenicity or antigenicity as an inactivated vaccine against infectious disease caused by a group of Japanese encephalitis viruses, in particular as an immunogen for an inactivated Japanese encephalitis vaccine or an antigen for a diagnostic agent, and a method for producing the same are provided. Such particles are generated through the step of culturing virus belonging to a group of Japanese encephalitis viruses (e.g., Japanese encephalitis virus) in a cell line, and/or a series of subsequent steps including concentration, purification, and inactivation. However, the scientific basis for this is unknown. Based on the above, the invention described herein provides the following:

(1) an inactivated virus particle, as a reinforced immunogen, prepared from a culture of cells infected with virus belonging to a group of Japanese encephalitis viruses, wherein a neutralizing antibody titer of the anti-serum obtained by immunization with the virus particles is about twice to about 10 times the neutralizing antibody titer of the anti-serum obtained by immunization with inactivated virus particles prepared from virus cultured in mouse brain;

(2) a method for producing an inactivated virus particle, including the steps of culturing virus belonging to a group

09555704.050200

of Japanese encephalitis viruses in a cell line, as well as inactivating and purifying the cell culture;

(3) a method as described in (2), wherein the cell line is a Vero cell;

5 (4) a method as described in (2) or (3), wherein the inactivating is conducted before the purification;

(5) a method as described in any of (2) to (4), wherein the inactivating is conducted at a temperature in a range of about 4°C to about 10°C;

10 (6) a method as described in any of (2) to (5), wherein the purifying is conducted by physical means;

(7) a method as described in any of (2) to (6), wherein the virus belonging to a group of Japanese encephalitis viruses is a Beijing strain or a ThCMAR67/93 strain of Japanese encephalitis virus;

15 (8) an inactivated virus particle produced by a production method as described in any of (2) to (7);

(9) an inactivated vaccine containing inactivated virus particles as described in (1) or (8); and

20 (10) a diagnostic agent for infectious disease caused by a group of Japanese encephalitis viruses, containing the entirety or a part of the inactivated virus particles as described in (8) as an antigen.

25 BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows electron micrographs of virus particles of the present invention (R particles; Fig. 1A) contained in a test vaccine and virus particles by conventional technologies (MB particles; Fig. 1B) contained in commercially available vaccine derived from mouse brain, with both viruses belonging to a Beijing strain.

000000-4025556

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The features of the embodiments of the present invention become apparent by comparing, in terms of both the materials and production method, an immunogen of Japanese encephalitis vaccine according to the present invention with a conventional immunogen as a representative example. Considering this, hereinafter, the difference in immunogenicity and morphology between the immunogen of the present invention and the conventional immunogen, virus particles as an immunogen, a host for virus culture, inactivation of virus, purification of virus, electron microscopic analysis, and a potency test will be described in this order.

15 An immunogen of a conventional Japanese encephalitis vaccine: This refers to an active ingredient (immunogen) of a commercially available inactivated vaccine against Japanese encephalitis. It is produced under the regulations of "Japanese encephalitis vaccine" or "Freeze-dried Japanese encephalitis vaccine", an English version of which was published by the Association of Biologicals Manufacturers of Japan in 1986, stipulated by Notice No. 217 "Minimum Requirements for Biological Products" by the Japanese Ministry of Health and Welfare based on the requirements of Sec. 42(1) of the Pharmaceutical Affairs Law (Law No. 145 enacted in 1960), and which is qualified through various tests for safety, effectiveness, and the like. The active ingredient or immunogen of this vaccine is virus particles of Japanese encephalitis (i.e., inactivated virus particles derived from mouse brain (MB)). The virus particles are obtained by inoculating mouse brain with a virus strain for producing

09555704-050200

a Japanese encephalitis vaccine, allowing the virus to propagate in large quantities in mouse brain, highly purifying the virus from a mouse brain homogenate, and inactivating the virus with an inactivating agent.

5 Hereinafter, the inactivated virus particles derived from mouse brain (MB) will be abbreviated as "MB particles" or "MB immunogen".

10 An immunogen of a Japanese encephalitis vaccine according to the present invention: This refers to an active ingredient (immunogen) of an inactivated Japanese encephalitis vaccine, which is produced under the above-mentioned "Japanese encephalitis vaccine" regulations except that a cell culture of a cell line is

15 used as a host for culturing Japanese encephalitis virus, and which is qualified through various quality control tests. This immunogen is virus particles of Japanese encephalitis (i.e., inactivated virus particles derived from a tissue culture), which are obtained by inoculating a cell culture

20 of a cell line with Japanese encephalitis virus, allowing the virus to propagate in large quantities, highly purifying the virus from the cell culture, and inactivating the virus with an inactivating agent. The immunogen has the following characteristic (1) and usually the following additional

25 characteristic (2).

(1) A neutralizing antibody titer of the anti-serum obtained by immunization with the above particles, as measured by a potency test described below, is about twice

30 to about 10 times the neutralizing antibody titer of the anti-serum obtained by immunization with the conventional MB particles or MB immunogen (hereinafter, the above immunogen will be referred to as "reinforced immunogen",

abbreviated as "R particles" or "R immunogen"); and

5 (2) Regarding a particle structure based on electron microscopic analysis, the surface or the appearance of an envelope layer of the MB particles was smooth, whereas that of the R particles was rough or fuzzy.

10 It should be noted that the immunogen of a Japanese encephalitis vaccine has been described as a representative example of an immunogen of a vaccine against infectious disease caused by a group of Japanese encephalitis viruses according to the present invention. The vaccine of the present invention (e.g., Japanese encephalitis vaccine) is provided in a sealed vial or heat-sealed ampoule in a liquid  
15 or dried state. In the case of a liquid formulation, it is subcutaneously injected into a subject to be vaccinated in an amount of about 0.2 to about 1.0 ml per person. In the case of a dry formulation, it is injected after being resolubilized with a solubilizing solution.

20 Virus as an immunogen: The group of Japanese encephalitis viruses according to the present invention includes Japanese encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, and West Nile virus, and the like. The details thereof are  
25 as described in Archives of Virology, Supplement 10, pp. 415-427, 1995 ("Virus Taxonomy", Classification and Nomenclature of Viruses; Sixth Report of the International Committee on Taxonomy of Viruses). Among them, regarding  
30 Japanese encephalitis virus, for example, the following strains can be used: Beijing-1 strain derived from mouse brain and JWS-P-4 strain obtained by our passaging Beijing-1 strain in mouse brain (Am29SmlAm5; more specifically, a

00555704 . 050200



virus strain obtained by 29 passages in an adult mouse (Am), one passage in a suckling mouse (Sm), and 5 passages in Am, master seed JMSV001 obtained by 2 passages of JWS-P-4 in a Vero cell (hereinafter, these 3 strains will be referred to as "Beijing strain"), Nakayama-Yoken strain (hereinafter, referred to as "Nakayama strain"), JaOArS982 strain, JaOH0566 strain, and ThCMAR67/93 strain and ThCMAR44/92 strain newly isolated by Igarashi et al. in the 1990s (Ali et al., Archives of Virology, 140, 1557-1575, 1995, and Ali and Igarashi, Microbiology and Immunology, 41, 241-252, 1977) and the like.

According to the present invention, among Japanese encephalitis virus strains, a Beijing strain and ThCMAR67/93 are particularly preferable as an immunogen. When these virus strains are used, a vaccine with a broad antigenic spectrum (i.e., having a very satisfactory protection against plural strains other than the virus strain used in production of the vaccine) can be obtained. Among Beijing strains, JMSV001 is preferable.

According to the present invention, a divalent vaccine may be prepared by mixing vaccines produced from two virus strains (e.g., Beijing strain and ThCMAR67/93 strain). Preferable is a mixing ratio of 0.5:1 to 1:0.5 on a basis of antigen protein contents. Because of such mixing, compared with a conventional monovalent vaccine alone, a vaccine having a broader antigenic spectrum for protecting against infection can be obtained.

A virus is cultured by inoculating an appropriate host cell line with the virus, and maintaining the infected cell in culture. A culturing method is the same as described

later in "Cell culture". Hereinafter, for convenience, virus from a supernatant obtained by low-speed centrifugation of a virus culture will be referred to as "extracellular virus". Virus from a supernatant obtained by suspending infected cells collected from centrifuged pellets, in an original volume in an Eagle's Minimum Essential Medium (MEM) supplemented with 0.2% (w/v) bovine serum albumin, followed by sonication and low-speed centrifugation, will be referred to as "intracellular virus".

An inactivated virus particle of the present invention can be obtained from either extracellular or intracellular virus. An extracellular virus is preferable since its yield is high; it is a mature virion; it is easy to be purified due to less contamination of cell derived components.

15

Host for virus culture: A known cell line can be used as a host for virus culture. For example, diploid cell lines such as WI-38, MRC-5, FRhL-2, etc., and serially passaged cell lines such as Vero, BHK-21, CHO, etc. can be used.

Serially passaged cell are preferable since their large-scale production is easy and programmable, as well as they are well-characterized and confirmed not to contain any other virus. Furthermore, commonly used CV-1, BSC-1, MA104, MDCK, CaCO-2, etc., and DBS-FLC-1, DBS-FLC-2, DBS-FRHL-2, ESK-4, HEL, IMR-90, WRL68, etc. conventionally used for producing a virus vaccine can also be used ("ATCC Microbes & Cells at Work", 2nd ed., p. 144, American Type Culture Collection (ATCC) 1991, USA). For the above-mentioned host for culturing a Japanese encephalitis virus strain, preferably, permissive cells are selected which allow the virus to grow well. For example, Vero (ATCC No. CCL-81), BHK-21[C-13](ATCC No. CCL-10), C6/36 (ATCC No. CRL-1660), etc. are preferably used. However, when using

30

0055704.000000

these cell lines, it is required to conduct various tests for contaminants, tumorigenicity, etc., in accordance with the Requirements for Biological Substances No. 50 regarding requirements for use of cells for the production of biologicals recommended by the World Health Organization (WHO), thereby confirming if these cell lines are qualified as cells for producing a vaccine (WHO Technical Report Series, No. 878, pp. 19-52, 1998).

10           Cell culture: For cell culture of the above-mentioned cell lines, stationary culture, perfusion system culture, shaking culture, roller tube culture, roller bottle culture, suspension culture, microcarrier culture, and the like can be adopted. For example, commercially available  
15   Cytodex (Pharmacia Biotech, Sweden) of various types are used as a microcarrier, and various commercially available animal cell culture devices can be used.

20           Inactivation of virus: An inactivating agent such as formalin,  $\beta$ -propiolactone, and glutardialdehyde is added to a virus suspension to inactivate the virus. For example, when using formalin, the amount to be added is about 0.005% to about 0.1% (v/v), the inactivation temperature is about 4°C to about 38°C, and the inactivation duration mainly  
25   depends upon the inactivation temperature (e.g., about 5 to about 180 hours at 38°C, and about 20 to 90 days at 4°C).

30           Purification of virus: Purification is conducted by physical means or chemical means. Physical means utilize physical properties, such as size, density, sedimentation constant, etc., of the substance to be purified, and includes, for example, zonal ultra-centrifugation, density gradient centrifugation, filtration, and the like. Physical means

are usually conducted without changes in pH and salt concentration of the surrounding environment. Chemical means utilize adsorption/desorption through chemical or physicochemical reaction and includes, for example, ion exchange column chromatography, affinity chromatography, salting, and the like. Purification is performed at about 4°C to room temperature.

Concentration of virus: Prior to inactivation and/or purification, concentration may be performed, for example, by low-speed centrifugation with an ultrafilter membrane.

According to the present invention, inactivation of the R particles is desirably conducted at about 4°C to about 10°C before purification. Furthermore, purification is desirably performed by a physical purification method. Particles thus obtained can maintain higher immunogenicity or antigenicity compared with particles inactivated after purification or chemically purified particles.

Electron microscopic analysis: For example, a virus sample prepared by a negative staining method using 2% (w/v) uranyl acetate can be observed under an electron microscope (Hitachi Ltd.). Virus particles can be analyzed on an image at a magnification of about 20,000 to about 100,000.

Preparation of vaccine: An inactivated virus particle of the present invention can be diluted with any suitable diluent so as to obtain a desired titer. Any known carrier or adjuvant may be added. A vaccine may optionally contain any preservative, stabilizer, etc.

Potency test: This test is conducted in accordance with "Potency Test" stipulated by the "Japanese encephalitis vaccine" regulations in the above-mentioned "Minimum Requirements for Biological Products". For example, fifteen 4-week old ddY mice are used in each group. The animals in each group are injected intraperitoneally with about 0.5 ml/mouse of each of the vaccines which have been serially 2-fold diluted, and after 7 days, the animals are boosted. Blood is collected from each mouse on the 7th day after the booster. Thereafter, an equal amount of serum is pooled for each group, and inactivated at about 56°C for about 30 minutes. The resultant serum is used for a neutralizing test as an immune serum. In the neutralizing test, a chick embryo cell culture is used as a host for virus culture, and virus used as a vaccine antigen or immunogen (e.g., Beijing strain, Nakayama strain, ThCMAR67/93 strain, and the like) can be used as a challenge virus. A neutralizing antibody titer is represented by the maximum dilution at which the above-mentioned immune serum reduces the number of plaques formed by the challenge virus by about 50%.

In another aspect, the virus particle (R particles) obtained according to the present invention can be used as a diagnostic antigen (e.g., an antigen in an immunoprecipitation method, a hemagglutination inhibition (HI) test, a complement fixation (CF) reaction, an ELISA, a radioimmunoassay, an immunofluorescence method, and the like). The R particles are characterized as diagnostic antigen in that reactivity of a particle with polyclonal antibodies and certain monoclonal antibodies is higher by about 2 to 10 times, compared with that of MB particles. More specifically, using the entirety or a part of an

09555704.050200

inactivated virus particle of the present invention, a diagnostic agent with high sensitivity for detecting infection by a group of Japanese encephalitis viruses, in particular infection by Japanese encephalitis virus, can be provided. As used herein, the term "a part" of an inactivated virus particle refers to a fraction of the virus which retains desired antigenicity derived from the virus particles, including, for example, structural proteins solubilized during the purification step described in Example 1.

Hereinafter, the embodiment, constitution, the structure and effect of the present invention will be described by way of illustrative experiments and examples. However, the present invention is not limited thereto.

#### Reference Example

The Sequence listing of both Beijing and ThCMar67/93 strains: in order to facilitate identification of a Beijing strain and a ThCMar67/93 strain of Japanese encephalitis virus particularly suitable for use in the present invention, SEQ ID NOs: 1 to 4 show base sequences of envelope protein gene cDNA complementary to genomic RNA of both strains and the deduced amino acid sequences encoded by the base sequences. SEQ ID NOs: 1 and 2 are for a ThCMar67/93 strain (Archives of Virology, 140, 1557-1575, 1995), and SEQ ID NOs: 3 and 4 are for master seed virus JMSV001 which is a Beijing strain. A "Beijing strain" used in Examples below is JMSV001.

The base sequence of cDNA was determined by a method described in the above-mentioned Ali et al. article. More specifically, genomic RNA was extracted from a virus culture

in Vero cells. Thereafter, a region encoding for an envelope protein was amplified by reverse transcription polymerase chain reaction (RT-PCR) using a pair of primers, and the base sequence of the resultant cDNA fragment was determined by a dideoxy chain termination method. Furthermore, the amino acid sequence encoded by the base sequence was decoded using universal codes.

#### Experiment 1

Measurement of a virus infection titer: A virus infection titer was counted in PFUs (plaque-forming unit)/ml by a plaque-counting method using Vero-M cells described later.

Measurement of a virus antigen amount: An amount of Japanese encephalitis virus antigen was measured by ELISA using an anti-Japanese encephalitis virus monoclonal antibody IgG (Group-8 Clone 503 (kindly provided by Dr. Yasui, Tokyo Metropolitan Institute for Neurosciences; K. Yasui et al., Journal of General Virology, 67, 2663-2672, 1986). An ELISA value was calculated by a parallel line assay as a relative value when the value of an in-house standard product (Beijing strain) derived from mouse brain is defined as 100 units.

HA test: A U-shaped microplate was used. Equal amounts of 0.33% (v/v) goose red blood cell suspension adjusted to optimum pH with a phosphate buffer and virus solution were mixed. Thereafter, they were allowed to be reacted with each other at 37°C for 60 minutes. Thus, the presence of hemagglutination was determined. An HA titer was represented as the maximum dilution of a virus solution which is positive for hemagglutination.

## Measurement of an amount of a bovine serum antigen:

The amount of a bovine serum antigen was measured by ELISA using anti-bovine serum goat IgG. The relative value with respect to the protein content in the bovine serum standard antigen was calculated by a parallel line assay, and the obtained value was determined as an amount of an antigen.

## Experiment 2

Proliferation in a cell line for virus culture:  
Adhesive 2-strain Vero cells: Vero-A (ATCC No. CCL-81) and Vero-M (Vero obtained from the National Institute of Infectious Diseases); 3-strain BHK-21 cells: BHK/WI2 (adhesive BHK-21 obtained from the Osaka prefectural Institute of Public Health), BHK/JHIH (suspended BHK-21 obtained from the National Institute of Animal Health) and BHK-21 [C-13] (ATCC No. CCL-10); and a C6/36 cell (ATCC No. CRL-1660) derived from a mosquito were used as candidate cell lines for virus culture, and viral propagation in each cell line was observed. Vero-A, Vero-M, BHK/WI2, and BHK-21 [C-13] were each prepared in a growth medium at about  $1.5 \times 10^5$  cells/ml. They were statically incubated at about 37°C for 3 days, and thereafter, the number of cells were respectively counted. In the same way as this, suspended BHK/JNIH was prepared at about  $2.0 \times 10^5$  cells/ml, and was incubated with shaking at about 37°C for 3 days. Thereafter, the number of cells was counted. C6/36 was prepared at about  $1.0 \times 10^5$  cells/ml, and was statically incubated at about 28°C for 7 days. Thereafter, the number of cells was counted. As a growth medium, MEM supplemented with a 8% (v/v) (final concentration) bovine serum was used. As a result, Vero-A, Vero-M, BHK/WI2, and BHK-21 [C-13] were counted and determined to be about  $7.0 \times 10^5$  cells/ml to about  $9.0 \times$



$10^5$  cells/ml, and suspended BHK/ANIH and C6/36 were counted and determined to be about  $2.8 \times 10^6$  cells/ml.

### Experiment 3

5            Propagation of Japanese encephalitis virus in  
candidate cell lines: C6/36 was incubated at about 28°C for  
7 days, and the other cells used in Experiment 2 were  
incubated at about 37°C for 3 days. Thereafter, each cell  
10        was inoculated with a Beijing strain at a multiplicity of  
infection (MOI) of 0.1, and measured for a virus infection  
titer (PFU), a virus antigen amount (ELISA titer), and an  
HA titer, whereby the time course of the change in  
extracellular virus amount was compared. Table 1 shows the  
results. Each numerical value is an average of the highest  
15        values in virus growth curves of each cell line for duplicate  
experiments. C6/36 exhibited the highest virus infection  
titer on the 3rd day from the commencement of incubation,  
and exhibited the highest ELISA titer and HA titer on the  
4th day. The other cell lines exhibited the highest virus  
20        infection titer on the 2nd day from the commencement of  
incubation, and exhibited the highest ELISA titer and HA  
titer on the 3rd and 4th day, respectively.

Table 1

Cell	PFU/ml	ELISA titer	HA titer
Adhesive			
Vero-A	$1.2 \times 10^8$	58	640
Vero-M	$5.7 \times 10^7$	35	320
BHK-21/WI2	$1.5 \times 10^8$	27	40
BHK-21 [C13]	$2.3 \times 10^8$	48	320
Suspended			
BHK-21/JNIH	$7.0 \times 10^7$	37	40
C6/36	$2.6 \times 10^8$	103	320

## Experiment 4

Type of Cytodex and proliferation of a Vero-A cell:  
 Any one of Cytodex 1, 2, or 3 was added to an amount of about  
 1.5 g/liter to each of 3 cell culture flasks, each containing  
 about 500 ml of Vero-A cell suspension at about  $1.5 \times 10^5$   
 cells/ml. Thereafter, each cell was incubated with  
 stirring at about 37° C and about 40 rpm for 7 days. The  
 following results were obtained. The number of cells per  
 milliliter on the 7th day from the commencement of incubation  
 was about  $7.5 \times 10^5$ , about  $8.3 \times 10^5$ , and about  $9.4 \times 10^5$  for  
 Cytodex 1, 2, and 3, respectively. Furthermore, when cells  
 were incubated with Cytodex 1 for 7 days, one hundred or  
 more Vero-A cells were grown adhering to the surface of all  
 the beads without any gaps.

## Experiment 5

Concentration of Cytodex and proliferation of a  
 Vero-A cell: Cytodex 1 was added to cell culture flasks A,  
 B, C, and D, each containing about 500 ml of cell suspension  
 at about  $1.5 \times 10^5$  cells/ml, to make a final amount of about  
 1.5 g/liter in the flasks A and B, about 3.0 g/liter in the

flask C, and about 4.5 g/liter in the flask D. Thereafter, each cell was incubated with stirring at about 37°C and about 40 rpm for 7 days. The number of cells and the fraction of beads to which cells adhered (i.e., the percentage of the beads adhered to) were counted. For calculating the percentage of the beads adhered to, at least 200 beads were observed for each flask, and the beads to which at least 5 cells adhered were counted as cell-adhered beads. The cells in the flask A in which Cytodex 1 was added to an amount of about 1.5 g/liter were incubated in the same growth medium throughout the incubation. In the flasks B, C, and D, half of the culture medium was replaced by a fresh growth medium on the 3rd, 4th, and 5th days after the commencement of incubation. The following results were obtained. Replacement of culture medium did not affect the number of cells (A and B). The number of cells per milliliter after 7-day incubation was about  $9.1 \times 10^5$  for the flask B, about  $7.7 \times 10^5$  for the flask C, and  $8.0 \times 10^5$  for the flask D. The percentage of the beads adhered to in the flasks A and B was about 98% or higher on the 1st day, and reached 100% on the 4th day. The percentage of the beads adhered to in the flasks C and D were lower (i.e., about 93% and about 80%, respectively). However, the percentage reached 100% in the flasks A, B, C, and D on the 6th day.

25

#### Experiment 6

Proliferation of Vero-A cells incubated at a high density with Cytodex 1: High-density incubation was conducted under the condition that the concentration of Cytodex 1 was added to a Vero-A cell suspension at about  $4.5 \times 10^5$  cells/ml to give a final concentration of about 4.5 g/liter, and the cells were incubated in an apparatus

0555704-050200

for incubating animal cells containing about 50 liters of a culture medium. The revolutions per minute were set to be about 15 rpm for the first 24 hours and about 20 rpm after 24 hours. pH was set to be 7.0, and dissolved oxygen was set to be about 5 ppm. Half of the culture medium was replaced by a fresh growth medium on the 3rd and 5th days after the commencement of incubation. The following results were obtained. The number of cells on the 5th and 7th days was about  $2.0 \times 10^6$  cells/ml and about  $2.6 \times 10^6$  cells/ml, respectively. Furthermore, the percentage of the beads to which cells adhered on the 2nd day was 100%.

#### Experiment 7

Propagation of a virus candidate strain for producing a vaccine in Vero-A cells: Vero-A statically incubated in a petri dish for 3 days were each inoculated with the above-mentioned four candidate strains (Beijing strain, Nakayama strain, JaOH0566, and JaOArS982) of Japanese encephalitis virus derived from mouse brain at an MOI of 0.1. Virus was adsorbed to Vero-A for about 90 minutes. Then, MEM supplemented with 2% (v/v) bovine serum was added to the resultant Vero-A, followed by incubation at about 37°C for 7 days. The time course of changes in infection titer and of an antigen amount was observed for extracellular virus and intracellular virus, were observed. The following results were obtained. Regarding the infection titer, extracellular virus of the three strains other than Nakayama strain exhibited the highest value (about  $1.0 \times 10^8$  PFU/ml or more) on the 2nd day after the commencement of incubation, and intracellular virus thereof exhibited a value which was 1/3 or less of that of the extracellular virus. Extracellular virus of Nakayama strain exhibited the highest infection titer on the 3rd day, which was 1/5

or less of that of the other three strains. Regarding the ELISA antigen titer, extracellular virus of the three strains other than Nakayama strain exhibited the highest value (about 70 units) on the 3rd to 5th days, and  
5 intracellular virus thereof exhibited a value which was 1/5 or less of that of the extracellular virus. The ELISA antigen titer of Nakayama strain plateaued (about 30 units) on the 5th to 7th days. Regarding the HA titer, extracellular virus of Nakayama strain exhibited a value of about 160 and  
10 that of the other three strains exhibited a value of about 640 to about 1280 on the 2nd to 4th days.

#### Experiment 8

Propagation of Beijing strain in a Vero-A cell  
15 incubated with Cytodex 1: 20 liters of Vero-A cells (about  $1.96 \times 10^6$  cells/ml) incubated with Cytodex 1 was inoculated with Beijing strain virus 4-passaged in Vero-A at an MOI of 0.1. The cells were incubated in a bovine serum-free MEM. The following results were obtained. Intracellular virus  
20 exhibited the highest infection titer (about  $1.3 \times 10^8$  PFU/ml) on the 2nd day of the incubation, and extracellular virus exhibited the highest infection titer (about  $4.0 \times 10^8$  PFU/ml) on the 3rd day. Extracellular virus exhibited the highest ELISA antigen titer (about 67 units) on the 4th  
25 day, and intracellular virus exhibited the highest ELISA antigen titer (about 26 units) on the 3rd day. Extracellular virus exhibited an HA titer of about 320 and intracellular virus exhibited an HA titer of about 40 on the 3rd day of the incubation.

30

#### Experiment 9

Genetic stability of a strain: The master seed (JMSV001) was prepared by passaging mouse-derived virus

09555704-060200

- (JWS-P-4) for 2 generations in Vero cells. The master seed was genetically stable even after 7 serial passages in Vero cells with no mutation found in the base sequence of a gene for each protein of Core, pre-M, and envelope. Furthermore, the amino acid sequences encoded by these genes were identical with those of JWS-P-4. Genetic analysis was conducted by the method described in Reference Example 1.

#### Example 1

- Preparation of a test vaccine: Vero-A cells incubated using Cytodex 1 were inoculated with Beijing strain prepared by passaging mouse-derived virus (JWS-P-4) for four generations in Vero-A at an MOI of 0.1, and was incubated in a bovine serum-free MEM at about 37°C for 4 days. A culture supernatant (i.e., extracellular virus) was collected. The supernatant was concentrated to about 1/10 volume through an ultrafiltration membrane with a cutoff of 100 kDa. Thereafter, formalin was added to a final concentration of 1/1500 (v/v), whereby the virus was inactivated. Inactivation was conducted at about 4°C for 50 days. Next, an inactivated virus suspension was twice subjected to the sucrose density gradient zonal ultracentrifugation, whereby the virus was purified. Both the first and second ultra-centrifugations were conducted at about 25% to about 50% (w/w) sucrose density gradient and about 30,000 rpm for about 13 hours, using P35ZT rotor (Nissei Sangyo Co., Ltd.). Virus fractions (sucrose density: 41%) were collected, and dialyzed against phosphate-buffered saline (PBS). The dialyzed fractions were used as a vaccine stock solution. The vaccine stock solution was subjected to various tests for safety and effectiveness in accordance with the above-mentioned "Minimum Requirements for Biological Products", and

qualified as a vaccine. Then, the vaccine stock solution was diluted in TC Medium 199 (Difco Laboratories, USA) so that the protein content therein became about 7.8 µg/ml. The resultant diluted vaccine solution was dispensed in 1 ml aliquots into 3 ml vials. Thereafter, each vial was sealed to obtain a test vaccine. The protein content in the test vaccine was measured in accordance with general testing methods (wherein protein was precipitated with heated trichloroacetic acid (TCA) and quantitated by the method of the Lowry process) in the above-mentioned "Minimum Requirements for Biological Products".

#### Example 2

Properties of the test vaccine during main steps:

Each sample which was collected at the time points of completing each of the main steps during production of the test vaccine described in Example 1 was subjected to various tests described in Experiment 1. The following results were obtained. The supernatant of virus culture (i.e., virus suspension) exhibited an infection titer of about  $2.2 \times 10^6$  PFU/ml, an ELISA antigen titer of about 70 units, and an HA titer of about 160. When the virus suspension was concentrated to 1/10 volume using an ultrafiltration membrane, an infection titer and an antigen amount became higher (about 10 times). After the first zonal ultracentrifugation, peaks of virus antigen amount were observed in two fractions having a sucrose concentration of about 41% and about 34%. Electron microscopy revealed that the fraction with a sucrose concentration of about 41% contained virus particles, and the fraction with a sucrose concentration of about 34% contained virally-antigenic particles which are very much smaller than the virus particles. Furthermore, a bovine serum antigen from a cell

0055704-060200

culture was detected in the fractions having the sucrose concentration of about 28% or less, and was separated from the virus particle fractions. The above-mentioned virus particle fractions were again subjected to purification by zonal ultra-centrifugation, and the presence of virus particles were confirmed as a single peak in the fractions having a sucrose concentration of about 40%. A test vaccine was prepared from the fractions. The test vaccine exhibited an ELISA antigen titer of about 45 units, and a protein content of about 7.8 µg/ml.

#### Example 3

Electron microscopy of the test vaccine: The test vaccine and a commercially available vaccine derived from mouse brain were subjected to the above-mentioned electron microscopic analysis (Figure 1). As a result, the surface or the appearance of an envelope layer of MB particles in the commercially available vaccine was smooth (B in Figure 1), whereas that of R particles in the test vaccine of the present invention was rough or fuzzy (A in Figure 1).

#### Example 4

Potency of a test vaccine based on a neutralization reaction: Each titer of three vaccines (test vaccine obtained in Example 1, commercially available vaccine derived from mouse brain, and reference vaccine for a potency test) containing inactivated Beijing strain virus as an active ingredient was measured in accordance with the above-mentioned "potency test". More specifically, each vaccine was serially diluted 2-fold in PBS, and inoculated into mice. Neutralizing antibody titers of the serum against Beijing strain virus were compared. Table 2 shows the relationship between dilution ratios of the vaccines



and common logarithm values of a neutralizing antibody titers.

5       The difference between common logarithmic values of  
neutralizing antibody titers of the anti-serum obtained by  
immunizing both test and commercially available vaccines  
(equivalent protein content) was about 0.38 to about 1.11  
for vaccine dilution of 8 to 32. That is, a neutralizing  
antibody titer obtained by the test vaccine immunogen was  
about twice to about 10 times that obtained by the  
10      commercially available vaccine immunogen. Furthermore, as  
a result of presuming these measured values by the parallel  
line assay, calculated magnification of titers  
(neutralizing antibody titers) of the test vaccine versus  
the commercially available vaccine, were about 3 times.

0055704.000000

Table 2

Protein content µg/ml	Vaccine dilution	Common logarithmic values of Neutralizing antibody titer	Difference (A-B)
Test	8	3.87	0.64
vaccine	16	3.51	0.38
(A)	32	3.33	1.11
Commercially	8	3.23	
available	16	3.13	
vaccine (B)	32	2.21	
Reference	16	1.87	
vaccine			

Difference (A-B): Common logarithmic value of (Neutralizing antibody titer of A) - Common logarithmic value of (Neutralizing antibody titer of B) at the identical dilution. For example, at a vaccine dilution of 8,  $3.87 - 3.24 = 0.64$ .

Protein content: measured by a TCA protein quantitation method (a protein in a vaccine is precipitated with heated trichloroacetic acid, and is quantitated by the method of Lowry process).

#### Example 5

Difference in immunogenicity between test vaccines based on a cross-neutralization reaction: Three strains (Beijing strain passaged for four generations in Vero-A cells, and ThCMar67/93 and ThCMar44/92 derived from Thailand, passaged for two generations in Vero-A cells) were used as seed virus, and test vaccines containing inactivated virus of each strain as an active ingredient were prepared in the same way as described in Example 1. Thereafter,

neutralizing antibody titers of the anti-serum obtained from mice immunized with the respective vaccines were measured and compared in the same way as described in Example 4, whereby cross-reactivity between the strains was analyzed.

5 For comparison, commercially available vaccines derived from mouse brain containing each inactivated virus of Beijing strain and Nakayama strain as its active ingredient, and a vaccine (Beijing strain) derived from mouse brain containing 5.4 µg/ml of a TCA protein as a reference vaccine

10 were used. Furthermore, for mouse immunization, the TCA protein content in each of five vaccines was adjusted to be about 7.5 µg/ml, and then, the vaccines were 16-fold diluted in PBS. As challenge virus in a neutralization test, the above-mentioned 4 viruses, i.e., Beijing, Nakayama,

15 ThCMAR67/93, and ThCMAR44/92 were used. Table 3 shows the results of the above-mentioned 5 vaccines in 16-fold dilution with PBS. In view of a cross-reaction spectrum, both the virus antigens of Beijing strain and ThCMAR67/93 strain were outstanding as an immunogen of an inactivated

20 Japanese encephalitis vaccine.

0955704-060200

Table 3

Vaccine	Virus			
	Beijing	Nakayama	Ar67	Ar44
Test vaccine (Beijing)	3.68	3.04	2.87	2.66
Commercially available vaccine (Beijing)	3.09	2.69	1.88	1.88
Commercially available vaccine (Nakayama)	0.86	2.05	1.45	1.04
Test vaccine (Ar67)	2.84	3.15	3.02	2.97
Reference vaccine (Beijing)	1.85	NT	NT	NT

Ar67: ThCMar67/93 strain; Ar44: ThCMar44/92 strain

Test vaccine: Inactivated vaccine produced in Vero cells

Commercially available vaccine: Inactivated vaccine derived from mouse brain

Reference vaccine: In-house standard inactivated vaccine derived from mouse brain

Numerical value: Common logarithmic value (log) of neutralizing antibody titer

NT: not tried

#### Example 6

Preparation of a test divalent vaccine: each vaccine stock solution of a Beijing strain and a ThCMar67/93 strain was prepared in the same way as in Example 1. Thereafter, each vaccine stock solution was diluted in PBS to obtain a protein content of 10 µg/mg. Then, the resultant solutions were mixed with each other in an equal amount,

and the mixture was dispensed to a vial to obtain a divalent vaccine. This divalent vaccine had a cross-reaction spectrum broader than that of the respective single monovalent vaccine.

5

#### Example 7

Preparation of a diagnostic agent: using the R particles in the Beijing strain vaccine stock solution prepared in Example 1 as a therapeutic antigen, its effectiveness was determined by ELISA in the same way as in "Measurement of a virus antigen amount" described above. As a comparative control antigen, MB particles in a commercially available Beijing strain vaccine were used. As antibodies, the monoclonal antibody 503 (Mab503: antibody to a neutralizing epitope common and specific to all the Japanese encephalitis virus), Mab302 (antibody to an epitope specific to a group of Japanese encephalitis viruses), and a polyclonal antibody (PAb: hyper-immune serum from a mouse) were used. While the antigen amount was kept constant (7.6 µg/ml of protein amount), the antibodies were serially diluted and each ELISA value was measured. Regarding an ELISA value of the R particles/an ELISA value of the MB particles, Mab503 exhibited 53/47, Mab302 exhibited 226/22, and PAb exhibited 120/52. Based on these results, the sensitivity of the R particles to Mab302 and PAb were judged to be about twice to about 10 times higher than that of the MB particles. Furthermore, it is considered from the results of Mab302 that the antigen of the present invention is useful as antigen for preparative detection of a group of Japanese encephalitis viruses.

30

00556701-000200

## Industrial Applicability

According to the present invention, virus particles are produced on a large scale by using an easy-to-handle and inexpensive cell line in place of an expensive mouse, which are also difficult to raise and control. Since a number of mice are not sacrificed, the present invention is desirable in view of animal protection. Furthermore, the production cost can be remarkably reduced, and measures against biohazards, the operation procedure for production, purification steps, quality control, the production plan, and the like are remarkably labor-efficient. According to the present invention, novel virus particles useful as a reinforced immunogen which exhibit a titer of about of twice to about 10 times that of a conventional inactivated vaccine, and a method for producing the same are provided. In particular, according to the present invention, novel Japanese encephalitis virus particles having outstanding immunogenicity or antigenicity as an immunogen for an inactivated Japanese encephalitis vaccine and an antigen for a diagnostic agent, and a method for producing the same are provided. Thus, according to the present invention, an inexpensive vaccine of outstanding quality and a diagnostic agent can be provided, which improves and dramatically spreads the prevention and diagnosis of infectious disease caused by a group of Japanese encephalitis viruses.

## WHAT IS CLAIMED IS:

1. An inactivated virus particle, as a reinforced immunogen, prepared from a culture of cells infected with virus belonging to a group of Japanese encephalitis viruses, wherein a neutralizing antibody titer of the anti-serum obtained by immunization with the virus particles is about twice to about 10 times the neutralizing antibody titer of the anti-serum obtained by immunization with inactivated virus particles prepared from virus cultured in mouse brain.
2. A method for producing an inactivated virus particle, comprising culturing virus belonging to a group of Japanese encephalitis viruses in a cell line, as well as inactivating and purifying the cell culture, wherein a neutralizing antibody titer of the anti-serum obtained by immunization with the virus particles is about twice to about 10 times the neutralizing antibody titer of the anti-serum obtained by immunization with inactivated virus particles prepared from virus cultured in mouse brain.
3. The method of claim 2, wherein the cell line is a Vero cell.
4. The method of claim 2 or 3, wherein the inactivating is conducted before the purifying.
5. The method of any of claims 2 to 4, wherein the inactivating is conducted at a temperature in a range of about 4°C to about 10°C.
6. The method of any of claims 2 to 5, wherein the purifying

0055701-060200

is conducted by physical means.

7. The method of any of claims 2 to 6, wherein the virus belonging to a group of Japanese encephalitis viruses is a Beijing strain or a ThCMAR67/93 strain of Japanese encephalitis virus.

8. An inactivated virus particle produced by the production method of any of claims 2 to 7.

9. An inactivated vaccine comprising the inactivated virus particles of claim 1 or 8.

10. A diagnostic agent for infectious disease caused by a group of Japanese encephalitis viruses, comprising the entirety or a part of the inactivated virus particles of claim 8 as an antigen.

0955704 000000




## ABSTRACT OF THE DISCLOSURE

5       The present invention provides a novel inactivated virus particle and a reinforced immunogen which have a reinforced titer about twice to about 10 times that of a conventional vaccine, as well as a method for producing the same. The inactivated virus particle of the present invention is useful in a diagnostic agent for infectious disease caused by a group of Japanese encephalitis viruses.


03553704.060200

Fig. 1

A



B



## SEQUENCE LISTING

&lt;110&gt; The Research Foundation for Microbial diseases of Osaka University

&lt;120&gt; Japanese Encephalitis

&lt;130&gt; P98AF308-2

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 4

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 1500

&lt;212&gt; DNA

&lt;213&gt; Japanese encephalitis virus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1500)

&lt;400&gt; 1

ttt aac tgt ctg gga atg ggg aat cgg gat ttc ata gaa gga gcc agt	48
Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe Ile Glu Gly Ala Ser	
1 5 10 15	

gga gcc act tgg gtg gat ttg gtg tia gaa gga gat agt tgt ttg aca	96
Gly Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Ser Cys Leu Thr	
20 25 30	

atc atg gca aac gac aaa cca aca cta gat gtc cgc atg atc aac att	144
Ile Met Ala Asn Asp Lys Pro Thr Leu Asp Val Arg Met Ile Asn Ile	
35 40 45	

gaa gct agc caa ctt gct gaa gtc agg agt tac tgc tat cac gct tca	192
Glu Ala Ser Gln Leu Ala Glu Val Arg Ser Tyr Cys Tyr His Ala Ser	
50 55 60	

gtc act gac att tca acg gtg gct cga tgc ccc acg act gga gaa gcc	240
Val Thr Asp Ile Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu Ala	
65 70 75 80	

cac aac gag aaa cgt gct gac agc agc tac gtg tgc aaa caa ggc ttt	288
His Asn Glu Lys Arg Ala Asp Ser Ser Tyr Val Cys Lys Gln Gly Phe	
85 90 95	



cia aaa atg gac aaa ctg gct ctg aag ggc acg act tat ggc atg tgt 912  
 Leu Lys Met Asp Lys Leu Ala Leu Lys Gly Thr Thr Tyr Gly Met Cys  
 290 295 300

aca gaa aaa ttc tcg ttc gcg aaa aat cca gcg gac aca ggc cat gga 960  
 Thr Glu Lys Phe Ser Phe Ala Lys Asn Pro Ala Asp Thr Gly His Gly  
 305 310 315 320

aca gtt gtc att gag ctg aca tat tct gga agc gat ggc tcc tgt aaa 1008  
 Thr Val Val Ile Glu Leu Thr Tyr Ser Gly Ser Asp Gly Ser Cys Lys  
 325 330 335

att ccg att gtc tca gtt gcg agc ctg aat gac atg acc cct gtc ggg 1056  
 Ile Pro Ile Val Ser Val Ala Ser Leu Asn Asp Met Thr Pro Val Gly  
 340 345 350

agg ctg gta aca gta aac ccc ttc gtt gcg aca tct agc tcc aac tca 1104  
 Arg Leu Val Thr Val Asn Pro Phe Val Ala Thr Ser Ser Ser Asn Ser  
 355 360 365

aag gtg ctg gtt gag atg gaa cct ccc ttc gga gac tct tat atc gtg 1152  
 Lys Val Leu Val Glu Met Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val  
 370 375 380

gtt gga aga ggg gac aag cag att aac cat cac tgg cac aaa gct gga 1200  
 Val Gly Arg Gly Asp Lys Gln Ile Asn His His Trp His Lys Ala Gly  
 385 390 395 400

agc acg ctg ggc aaa gcc ttc tca aca act ttg aaa ggg gct cag aga 1248  
 Ser Thr Leu Gly Lys Ala Phe Ser Thr Thr Leu Lys Gly Ala Gln Arg  
 405 410 415

tta gca gcg cta ggt gac aca gcc tgg gac ttc ggc tcc att gga ggg 1296  
 Leu Ala Ala Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly  
 420 425 430

gta ttc aac tcc ata ggg aaa gct gtt cac caa gta ttt ggc ggt gca 1344  
 Val Phe Asn Ser Ile Gly Lys Ala Val His Gln Val Phe Gly Gly Ala  
 435 440 445

ttc aga acg ctg ttt ggg gga atg tct tgg atc aca caa gga cta atg 1392  
 Phe Arg Thr Leu Phe Gly Gly Met Ser Trp Ile Thr Gln Gly Leu Met  
 450 455 460

ggg gcc ttg ctt ctt tgg atg ggt gtc aac gca cga gac cgg tca atc 1440  
 Gly Ala Leu Leu Leu Trp Met Gly Val Asn Ala Arg Asp Arg Ser Ile  
 465 470 475 480

gcc ctg gct ttt ttg gcc acg gga ggt gtg ctc gtg ttt tta gcg acc 1488  
 Ala Leu Ala Phe Leu Ala Thr Gly Gly Val Leu Val Phe Leu Ala Thr  
 485 490 495

aat gtg cat gcc 1500  
 Asn Val His Ala  
 500

<210> 2

<211> 500

<212> PRT

<213> Japanese encephalitis virus

<400> 2

Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe Ile Glu Gly Ala Ser  
 1 5 10 15

Gly Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Ser Cys Leu Thr  
 20 25 30

Ile Met Ala Asn Asp Lys Pro Thr Leu Asp Val Arg Met Ile Asn Ile  
 35 40 45

Glu Ala Ser Gln Leu Ala Glu Val Arg Ser Tyr Cys Tyr His Ala Ser  
 50 55 60

Val Thr Asp Ile Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu Ala  
 65 70 75 80

His Asn Glu Lys Arg Ala Asp Ser Ser Tyr Val Cys Lys Gln Gly Phe  
 85 90 95

Thr Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser  
 100 105 110

Ile Asp Thr Cys Ala Lys Phe Ser Cys Thr Ser Lys Ala Ile Gly Arg  
 115 120 125

Met Ile Gln Pro Glu Asn Ile Lys Tyr Glu Val Gly Ile Phe Val His  
 130 135 140

Gly Thr Thr Thr Ser Glu Asn His Gly Asn Tyr Ser Ala Gln Val Gly  
 145 150 155 160

Ala Ser Gln Ala Ala Lys Phe Thr Val Thr Pro Asn Ala Pro Ser Ile  
 165 170 175

Thr Leu Lys Leu Gly Asp Tyr Gly Glu Val Thr Leu Asp Cys Glu Pro  
 180 185 190  
 Arg Ser Gly Leu Asn Thr Glu Ala Phe Tyr Val Met Thr Val Gly Ser  
 195 200 205  
 Lys Ser Phe Leu Val His Arg Glu Trp Phe His Asp Leu Ser Leu Pro  
 210 215 220  
 Trp Thr Ser Pro Ser Ser Thr Ala Trp Arg Asn Arg Glu Leu Leu Met  
 225 230 235 240  
 Glu Phe Glu Glu Ala His Ala Thr Lys Gln Ser Val Val Ala Leu Gly  
 245 250 255  
 Ser Gln Glu Gly Gly Leu His Gln Ala Leu Ala Gly Ala Ile Val Val  
 260 265 270  
 Glu Tyr Ser Ser Ser Val Lys Leu Thr Ser Gly His Leu Lys Cys Arg  
 275 280 285  
 Leu Lys Met Asp Lys Leu Ala Leu Lys Gly Thr Thr Tyr Gly Met Cys  
 290 295 300  
 Thr Glu Lys Phe Ser Phe Ala Lys Asn Pro Ala Asp Thr Gly His Gly  
 305 310 315 320  
 Thr Val Val Ile Glu Leu Thr Tyr Ser Gly Ser Asp Gly Ser Cys Lys  
 325 330 335  
 Ile Pro Ile Val Ser Val Ala Ser Leu Asn Asp Met Thr Pro Val Gly  
 340 345 350  
 Arg Leu Val Thr Val Asn Pro Phe Val Ala Thr Ser Ser Ser Asn Ser  
 355 360 365  
 Lys Val Leu Val Glu Met Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val  
 370 375 380  
 Val Gly Arg Gly Asp Lys Gln Ile Asn His His Trp His Lys Ala Gly  
 385 390 395 400  
 Ser Thr Leu Gly Lys Ala Phe Ser Thr Thr Leu Lys Gly Ala Gln Arg  
 405 410 415  
 Leu Ala Ala Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly  
 420 425 430

Val Phe Asn Ser Ile Gly Lys Ala Val His Gln Val Phe Gly Gly Ala  
435 440 445

Phe Arg Thr Leu Phe Gly Gly Met Ser Trp Ile Thr Gln Gly Leu Met  
450 455 460

Gly Ala Leu Leu Leu Trp Met Gly Val Asn Ala Arg Asp Arg Ser Ile  
465 470 475 480

Ala Leu Ala Phe Leu Ala Thr Gly Gly Val Leu Val Phe Leu Ala Thr  
485 490 495

Asn Val His Ala  
500

<210> 3

<211> 1500

<212> DNA

<213> Japanese encephalitis virus

<220>

<221> CDS

<222> (1).. (1500)

<400> 3

ttc aac tgt ctg gga atg ggc aat cgt gac ttc ata gaa gga gcc agt 48  
Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe Ile Gln Gly Ala Ser  
1 5 10 15

gga gcc act tgg gtg gac ttg gtg cta gaa gga gac agc tgc ttg aca 96  
Gly Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Ser Cys Leu Thr  
20 25 30

atc atg gca aac gac aaa cca aca ttg gac gtc cgc atg atc aac atc 144  
Ile Met Ala Asn Asp Lys Pro Thr Leu Asp Val Arg Met Ile Asn Ile  
35 40 45

gaa gct agc caa cit gct gag gtc aga agt tac tgc tat cat gct tca 192  
Glu Ala Ser Gln Leu Ala Glu Val Arg Ser Tyr Cys Tyr His Ala Ser  
50 55 60

gtc act gac atc tcg acg gtg gct cgg tgc ccc acg act gga gaa gcc 240  
Val Thr Asp Ile Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu Ala  
65 70 75 80

cac aac gag aag cga gct gal agt agc tat gtg tgc aaa caa ggc ttc 288  
His Asn Glu Lys Arg Ala Asp Ser Ser Tyr Val Cys Lys Gln Gly Phe  
85 90 95



act gat cgt ggg tgg ggc aac gga tgt gga ctt ttc ggg aag gga agt 336  
 Thr Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser  
 100 105 110

att gac aca tgt gca aaa ttc tcc tgc acc agg aaa gcg att ggg aga 384  
 Ile Asp Thr Cys Ala Lys Phe Ser Cys Thr Arg Lys Ala Ile Gly Arg  
 115 120 125

aca atc cag cca gaa aac atc aaa tac gaa gtt ggc att ttt gtg cat 432  
 Thr Ile Gln Pro Glu Asn Ile Lys Tyr Glu Val Gly Ile Phe Val His  
 130 135 140

gga acc acc act tcg gaa aac cat ggg aat tat tca gcg caa gtt ggg 480  
 Gly Thr Thr Thr Ser Glu Asn His Gly Asn Tyr Ser Ala Gln Val Gly  
 145 150 155 160

gcg tcc cag gcg gca aag ttt aca gta aca cct aat gct cct tcg ata 528  
 Ala Ser Gln Ala Ala Lys Phe Thr Val Thr Pro Asn Ala Pro Ser Ile  
 165 170 175

acc ctc aaa ctt ggt gac tac gga gaa gtc aca ctg gac tgt gag cca 576  
 Thr Leu Lys Leu Gly Asp Tyr Gly Glu Val Thr Leu Asp Cys Glu Pro  
 180 185 190

agg agt gga cta aac act gaa gcg ttt tac gtc atg acc gtg ggg tca 624  
 Arg Ser Gly Leu Asn Thr Glu Ala Phe Tyr Val Met Thr Val Gly Ser  
 195 200 205

aag tca ttt ttg gtc cat agg gaa tgg ttt cat gac ctc gct ctc cct 672  
 Lys Ser Phe Leu Val His Arg Glu Trp Phe His Asp Leu Ala Leu Pro  
 210 215 220

tgg acg ccc cct tcg agc aca gcg tgg aga aac aga gaa ctc ctc atg 720  
 Trp Thr Pro Pro Ser Ser Thr Ala Trp Arg Asn Arg Glu Leu Leu Met  
 225 230 235 240

gaa ttt gaa gag gcg cac gcc aca aaa cag tcc gtt gtt gct ctt ggg 768  
 Glu Phe Glu Glu Ala His Ala Thr Lys Gln Ser Val Val Ala Leu Gly  
 245 250 255

tca cag gaa gga ggc ctc cat cag gcg ttg gca gga gcc atc gtg gtg 816  
 Ser Gln Glu Gly Gly Leu His Gln Ala Leu Ala Gly Ala Ile Val Val  
 260 265 270

gag tac tca agc tca gtg aag tta aca tca ggc cac cta aaa tgc agg 864  
 Glu Tyr Ser Ser Ser Val Lys Leu Thr Ser Gly His Leu Lys Cys Arg  
 275 280 285

cig aaa aig gac aaa cig gct cig aaa ggc aca acc tat ggt aig tgc 912  
 Leu Lys Met Asp Lys Leu Ala Leu Lys Gly Thr Thr Tyr Gly Met Cys  
 290 295 300

aca gaa aaa ttc tgc ttc gcg aaa aat cgg gcg gac act ggt cac gga 960  
 Thr Glu Lys Phe Ser Phe Ala Lys Asn Pro Ala Asp Thr Gly His Gly  
 305 310 315 320

aca gtt gtc att gaa ctt tca tac tct ggg agt gat ggc ccc tgc aag 1008  
 Thr Val Val Ile Glu Leu Ser Tyr Ser Gly Ser Asp Gly Pro Cys Lys  
 325 330 335

att cgg att gtc tcc gtt gct agc ctc aat gac atg acc ccc gtc ggg 1056  
 Ile Pro Ile Val Ser Val Ala Ser Leu Asn Asp Met Thr Pro Val Gly  
 340 345 350

cgg cig gtg aca gtg aac ccc ttc gtc gcg act tcc agc gcc aac tca 1104  
 Arg Leu Val Thr Val Asn Pro Phe Val Ala Thr Ser Ser Ala Asn Ser  
 355 360 365

aag gtg cig gtc gag atg gaa ccc ccc ttc gga gac tcc tac atc gta 1152  
 Lys Val Leu Val Glu Met Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val  
 370 375 380

gtt gga agg gga gac aag cag att aac cac cat tgg tac aag gct gga 1200  
 Val Gly Arg Gly Asp Lys Glu Ile Asn His His Trp Tyr Lys Ala Gly  
 385 390 395 400

agc acg cig ggc aaa gcc ttt tca acg act ttg aag gga gct caa aga 1248  
 Ser Thr Leu Gly Lys Ala Phe Ser Thr Thr Leu Lys Gly Ala Glu Arg  
 405 410 415

cig gca gcg ttg ggc gac aca gcc tgg gac ttt ggc tct att gga ggg 1296  
 Leu Ala Ala Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly  
 420 425 430

gtc ttc aac tcc ata ggg aaa gct gtt cac caa gtg ttt ggt ggt gcc 1344  
 Val Phe Asn Ser Ile Gly Lys Ala Val His Glu Val Phe Gly Gly Ala  
 435 440 445

ttc aga aca ctc ttt ggg gga atg tct tgg atc aca caa ggg cta atg 1392  
 Phe Arg Thr Leu Phe Gly Gly Met Ser Trp Ile Thr Glu Gly Leu Met  
 450 455 460

ggg gcc cta cta ctt tgg atg ggc atc aac gca cga gac cga tca att 1440  
 Gly Ala Leu Leu Leu Trp Met Gly Ile Asn Ala Arg Asp Arg Ser Ile  
 465 470 475 480

gct tlg gcc tlc lta gcc aca gga ggt glg ctc glg tlc lta gct acc 1488  
 Ala Leu Ala Phe Leu Ala Thr Gly Gly Val Leu Val Phe Leu Ala Thr  
 485 490 495

aat glg cat gct 1500  
 Asn Val His Ala  
 500

<210> 4

<211> 500

<212> PRT

<213> Japanese encephalitis virus

<400> 4

Phe Asn Cys Leu Gly Met Gly Asn Arg Asp Phe Ile Glu Gly Ala Ser  
 1 5 10 15

Gly Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Ser Cys Leu Thr  
 20 25 30

Ile Met Ala Asn Asp Lys Pro Thr Leu Asp Val Arg Met Ile Asn Ile  
 35 40 45

Glu Ala Ser Gln Leu Ala Glu Val Arg Ser Tyr Cys Tyr His Ala Ser  
 50 55 60

Val Thr Asp Ile Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu Ala  
 65 70 75 80

His Asn Glu Lys Arg Ala Asp Ser Ser Tyr Val Cys Lys Gln Gly Phe  
 85 90 95

Thr Asp Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser  
 100 105 110

Ile Asp Thr Cys Ala Lys Phe Ser Cys Thr Arg Lys Ala Ile Gly Arg  
 115 120 125

Thr Ile Gln Pro Glu Asn Ile Lys Tyr Glu Val Gly Ile Phe Val His  
 130 135 140

Gly Thr Thr Thr Ser Glu Asn His Gly Asn Tyr Ser Ala Gln Val Gly  
 145 150 155 160

Ala Ser Gln Ala Ala Lys Phe Thr Val Thr Pro Asn Ala Pro Ser Ile  
 165 170 175

Thr Leu Lys Leu Gly Asp Tyr Gly Glu Val Thr Leu Asp Cys Glu Pro  
 180 185 190  
 Arg Ser Gly Leu Asn Thr Glu Ala Phe Tyr Val Met Thr Val Gly Ser  
 195 200 205  
 Lys Ser Phe Leu Val His Arg Glu Trp Phe His Asp Leu Ala Leu Pro  
 210 215 220  
 Trp Thr Pro Pro Ser Ser Thr Ala Trp Arg Asn Arg Glu Leu Leu Met  
 225 230 235 240  
 Glu Phe Glu Glu Ala His Ala Thr Lys Gln Ser Val Val Ala Leu Gly  
 245 250 255  
 Ser Gln Glu Gly Gly Leu His Gln Ala Leu Ala Gly Ala Ile Val Val  
 260 265 270  
 Glu Tyr Ser Ser Ser Val Lys Leu Thr Ser Gly His Leu Lys Cys Arg  
 275 280 285  
 Leu Lys Met Asp Lys Leu Ala Leu Lys Gly Thr Thr Tyr Gly Met Cys  
 290 295 300  
 Thr Glu Lys Phe Ser Phe Ala Lys Asn Pro Ala Asp Thr Gly His Gly  
 305 310 315 320  
 Thr Val Val Ile Glu Leu Ser Tyr Ser Gly Ser Asp Gly Pro Cys Lys  
 325 330 335  
 Ile Pro Ile Val Ser Val Ala Ser Leu Asn Asp Met Thr Pro Val Gly  
 340 345 350  
 Arg Leu Val Thr Val Asn Pro Phe Val Ala Thr Ser Ser Ala Asn Ser  
 355 360 365  
 Lys Val Leu Val Glu Met Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val  
 370 375 380  
 Val Gly Arg Gly Asp Lys Gln Ile Asn His His Trp Tyr Lys Ala Gly  
 385 390 395 400  
 Ser Thr Leu Gly Lys Ala Phe Ser Thr Thr Leu Lys Gly Ala Gln Arg  
 405 410 415  
 Leu Ala Ala Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly  
 420 425 430

Val Phe Asn Ser Ile Gly Lys Ala Val His Gln Val Phe Gly Gly Ala  
 435 440 445

Phe Arg Thr Leu Phe Gly Gly Met Ser Trp Ile Thr Gln Gly Leu Met  
 450 455 460

Gly Ala Leu Leu Leu Trp Met Gly Ile Asn Ala Arg Asp Arg Ser Ile  
 465 470 475 480

Ala Leu Ala Phe Leu Ala Thr Gly Gly Val Leu Val Phe Leu Ala Thr  
 485 490 495

Asn Val His Ala  
 500

**COMBINED DECLARATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER  
2150-0008.10

AUG 17 2000

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below except for my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**ENHANCED IMMUNOGEN FOR INACTIVATED VACCINE FOR INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES AND PROCESS FOR PRODUCING THE SAME**

the specification of which (check only one item below):

- ☐ is attached hereto.  
☐ was filed as United States application Serial No. \_\_\_\_\_  
on \_\_\_\_\_  
and was amended  
on \_\_\_\_\_ (if applicable)  
☒ was filed as PCT international application Number PCT/JP99/02931  
on 02 June 2000  
and was amended under PCT Article 19 on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America listed below and have also identified below, by checking the box, any foreign application(s) for patent or inventor's certificate, or of any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed.

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119:**

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC § 119	
JP	10-319762	05 October 1998	<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or 365(c) of any PCT international application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT application(s) in the manner provided by the first paragraph of 35, U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56(a) which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:**

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL Nos. ASSIGNED (if any)		
PCT/JP99/02931	02 June 1999		X	

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Peter J. Dehlinger 28,006

Judy M. Mohr 38,563

LeeAnn Gorthey 37,337

Linda R. Judge 42,702

Michael L. Gencarella P44,703

Michael T. Gabrik 32,896

Gregory L. Heinkel 44,755

## COMBINED DECLARATION AND POWER OF ATTORNEY (CONTINUED)

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NO.

2150-0008.10

Send Correspondence to:

Iota PI Law Group  
P.O. Box 60850  
Palo Alto, CA 94306Direct Telephone Calls to:  
Judy M. Mohr  
(650) 324-0880

201	FULL NAME OF INVENTOR	FAMILY NAME <u>Ishikawa</u> 1-00	FIRST GIVEN NAME <u>Toyokazu</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OF FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP JP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-9-41, Yahata-cho Kanonji-shi</u>	CITY <u>Kagawa-ken</u> SPX	STATE & ZIP CODE/COUNTRY <u>768-0061 Japan</u>
202	FULL NAME OF INVENTOR	FAMILY NAME <u>Yoshii</u> 2-00	FIRST GIVEN NAME <u>Hironori</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OF FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP JP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-9-41, Yahata-cho Kanonji-shi</u>	CITY <u>Kagawa-ken</u> SPX	STATE & ZIP CODE/COUNTRY <u>768-0061 Japan</u>
203	FULL NAME OF INVENTOR	FAMILY NAME <u>Onishi</u> 3-00	FIRST GIVEN NAME <u>Toshiyuki</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OF FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP JP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-9-41, Yahata-cho Kanonji-shi</u>	CITY <u>Kagawa-ken</u> SPX	STATE & ZIP CODE/COUNTRY <u>768-0061 Japan</u>
204	FULL NAME OF INVENTOR	FAMILY NAME <u>Imagawa</u> 4-00	FIRST GIVEN NAME <u>Tadashi</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OF FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP JP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-9-41, Yahata-cho Kanonji-shi</u>	CITY <u>Kagawa-ken</u> SPX	STATE & ZIP CODE/COUNTRY <u>768-0061 Japan</u>
205	FULL NAME OF INVENTOR	FAMILY NAME <u>Ishibashi</u> 5-00	FIRST GIVEN NAME <u>Masahide</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OF FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP JP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-9-41, Yahata-cho Kanonji-shi</u>	CITY <u>Kagawa-ken</u> SPX	STATE & ZIP CODE/COUNTRY <u>768-0061 Japan</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the filing of a false affidavit are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 <u>Toyokazu Ishikawa</u>	SIGNATURE OF INVENTOR 202 <u>Hironori Yoshii</u>	SIGNATURE OF INVENTOR 203 <u>Toshiyuki Onishi</u>	SIGNATURE OF INVENTOR 204 <u>Tadashi Imagawa</u>
DATE July 24, 2000	DATE July 24, 2000	DATE July 24, 2000	DATE July 24, 2000

SIGNATURE OF INVENTOR 205

Masahide Ishibashi  
DATE  
July 24, 2000